Participants
zoster
ZOSTER
The study was conducted between 7 October 2021 and 29 August 2022 at 47 sites in the US. From a total of 545 participants randomized, 539 were vaccinated (exposed set; 272 in the Seq and 267 in the Coad group), and 91.2% in the Seq and 92.6% in the Coad group completed the study (Participant flow. The Seq group received the mRNA-1273 booster dose followed 2 weeks later by the first dose of RZV. The Coad group received coadministration of the mRNA-1273 booster and the first dose of RZV. Abbreviations: D, study day; LTFU, lost to follow-up; mRNA-1273, Moderna's messenger RNA COVID-19 vaccine; PPS, per-protocol set; RZV, recombinant zoster vaccine.The study groups were well balanced in terms of demography (Demographic Characteristics of Study Participants (Exposed Set)Data are presented as No. (%) unless otherwise indicated. The Seq group received the mRNA-1273 booster dose followed 2 weeks later by the first dose of recombinant zoster vaccine (RZV). The Coad group received coadministration of the mRNA-1273 booster and the first dose of RZV.Abbreviations: Min, Max, minimum and maximum values; mRNA-1273, Moderna's mRNA COVID-19 vaccine; SD, standard deviation.